These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 32302486)
21. Roflumilast enhances cisplatin-sensitivity and reverses cisplatin-resistance of ovarian cancer cells via cAMP/PKA/CREB-FtMt signalling axis. Gong S; Chen Y; Meng F; Zhang Y; Li C; Zhang G; Huan W; Wu F Cell Prolif; 2018 Oct; 51(5):e12474. PubMed ID: 30069985 [TBL] [Abstract][Full Text] [Related]
22. ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells. Xu Y; Gao W; Zhang Y; Wu S; Liu Y; Deng X; Xie L; Yang J; Yu H; Su J; Sun L Int J Oncol; 2018 Sep; 53(3):1055-1068. PubMed ID: 30015875 [TBL] [Abstract][Full Text] [Related]
23. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line. Du P; Zhang X; Liu H; Chen L DNA Cell Biol; 2015 Jul; 34(7):497-502. PubMed ID: 25941922 [TBL] [Abstract][Full Text] [Related]
24. Biphasically Modulating the Activity of Carboxypeptidase G2 with Ultrasound. Ma W; Zhang Y; Zheng X; Yu T Cell Physiol Biochem; 2017; 42(4):1614-1622. PubMed ID: 28738357 [TBL] [Abstract][Full Text] [Related]
25. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Francis RJ; Sharma SK; Springer C; Green AJ; Hope-Stone LD; Sena L; Martin J; Adamson KL; Robbins A; Gumbrell L; O'Malley D; Tsiompanou E; Shahbakhti H; Webley S; Hochhauser D; Hilson AJ; Blakey D; Begent RH Br J Cancer; 2002 Sep; 87(6):600-7. PubMed ID: 12237768 [TBL] [Abstract][Full Text] [Related]
26. [Effects of recombinant human interleukin-24 alone and in combination with cisplatin on the growth of ovarian cancer cells in vitro]. Wang S; Guo J; Tang Y; Zheng R; Song M; Sun W Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jan; 30(1):33-6. PubMed ID: 24405596 [TBL] [Abstract][Full Text] [Related]
27. Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro. Tang YJ; Sun ZL; Wu WG; Xing J; He YF; Xin DM; Han P Genet Mol Res; 2015 Mar; 14(1):2450-60. PubMed ID: 25867391 [TBL] [Abstract][Full Text] [Related]
28. Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein. Bhatia J; Sharma SK; Chester KA; Pedley RB; Boden RW; Read DA; Boxer GM; Michael NP; Begent RH Int J Cancer; 2000 Feb; 85(4):571-7. PubMed ID: 10699932 [TBL] [Abstract][Full Text] [Related]
29. Development of ZD2767P-carboxypeptidase G2-ultrasound therapy against cisplatin-resistant cancer. Yu T; Li X Front Oncol; 2023; 13():1151613. PubMed ID: 37274240 [No Abstract] [Full Text] [Related]
30. Synthesis and biological evaluation of novel pyrrolo[2,1-c][1,4]benzodiazepine prodrugs for use in antibody-directed enzyme prodrug therapy. Masterson LA; Spanswick VJ; Hartley JA; Begent RH; Howard PW; Thurston DE Bioorg Med Chem Lett; 2006 Jan; 16(2):252-6. PubMed ID: 16290933 [TBL] [Abstract][Full Text] [Related]
31. Ultrasound increases DNA damage attributable to cisplatin in cisplatin-resistant human ovarian cancer cells. Yu T; Yang Y; Liu S; Yu H Ultrasound Obstet Gynecol; 2009 Mar; 33(3):355-9. PubMed ID: 19204912 [TBL] [Abstract][Full Text] [Related]
32. Circumvention of cisplatin resistance in ovarian cancer by combination of cyclosporin A and low-intensity ultrasound. Yu T; Yang Y; Zhang J; He H; Ren X Eur J Pharm Biopharm; 2015 Apr; 91():103-10. PubMed ID: 25668779 [TBL] [Abstract][Full Text] [Related]
33. Effect of tamoxifen, methoxyprogesterone acetate and combined treatment on cellular proliferation and apoptosis in SKOV3/DDP cells via the regulation of vascular endothelial growth factor. Wen L; Hong D; Yanyin W; Mingyue Z; Baohua L Arch Gynecol Obstet; 2013 May; 287(5):997-1004. PubMed ID: 23212665 [TBL] [Abstract][Full Text] [Related]
34. The BH3 mimetic S1 induces endoplasmic reticulum stress-associated apoptosis in cisplatin-resistant human ovarian cancer cells although it activates autophagy. Liu N; Xu Y; Sun JT; Su J; Xiang XY; Yi HW; Zhang ZC; Sun LK Oncol Rep; 2013 Dec; 30(6):2677-84. PubMed ID: 24100381 [TBL] [Abstract][Full Text] [Related]
35. MicroRNA-132 reverses cisplatin resistance and metastasis in ovarian cancer by the targeted regulation on Bmi-1. Zhang XL; Sun BL; Tian SX; Li L; Zhao YC; Shi PP Eur Rev Med Pharmacol Sci; 2019 May; 23(9):3635-3644. PubMed ID: 31114988 [TBL] [Abstract][Full Text] [Related]
36. [Effects of survivin siRNA on growth, apoptosis and chemosensitivity of ovarian cancer cells SKOV3/DDP]. Zhang X; Li N; Wang YH; Huang Y; Xu NZ; Wu LY Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):174-7. PubMed ID: 19615253 [TBL] [Abstract][Full Text] [Related]
37. [Expression of microRNA-100 and its correlation with drug resistance in human ovarian cancer SKOV3/DDP cells]. Guo P; Peng D; Xiong X; Zhang S Nan Fang Yi Ke Da Xue Xue Bao; 2015 Nov; 35(11):1624-7. PubMed ID: 26607088 [TBL] [Abstract][Full Text] [Related]
38. MicroRNA 1301 inhibits cisplatin resistance in human ovarian cancer cells by regulating EMT and autophagy. Yu JL; Gao X Eur Rev Med Pharmacol Sci; 2020 Feb; 24(4):1688-1696. PubMed ID: 32141535 [TBL] [Abstract][Full Text] [Related]
39. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis. Eoh KJ; Lee SH; Kim HJ; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ Biochem Biophys Res Commun; 2018 Mar; 497(2):513-520. PubMed ID: 29452092 [TBL] [Abstract][Full Text] [Related]
40. Autophagic flux promotes cisplatin resistance in human ovarian carcinoma cells through ATP-mediated lysosomal function. Ma L; Xu Y; Su J; Yu H; Kang J; Li H; Li X; Xie Q; Yu C; Sun L; Li Y Int J Oncol; 2015 Nov; 47(5):1890-900. PubMed ID: 26397057 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]